621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently…
The insights gleaned from this large-scale, multi-country observational study will be invaluable for understanding the real-world effectiveness and safety profile of semaglutide for weight management. This data will h…
This study is critically important because obesity significantly impacts the health and longevity of kidney transplant recipients, increasing risks of complications and graft loss. If successful, this combined approac…
If successful, this Phase 3 trial could represent a paradigm shift in post-stroke care, offering a novel therapeutic strategy to enhance recovery beyond clot removal. Given the high global burden of stroke-related dis…
This Phase 4 pragmatic trial is crucial because it provides real-world evidence on semaglutide's long-term performance against a broad spectrum of existing Type 2 Diabetes treatments. Such data helps clinicians and pa…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
This case highlights a crucial, though likely rare, adverse event associated with rapid weight loss induced by semaglutide, a widely used GLP-1 receptor agonist. Clinicians prescribing semaglutide should be aware of t…
This study provides crucial evidence suggesting that Tirzepatide offers superior weight loss efficacy compared to oral semaglutide, which can significantly inform clinical decision-making for managing overweight and o…
The successful completion of enrollment for this Phase 3 trial is a crucial step towards potentially offering a highly effective new treatment option for obesity. If the results demonstrate significant weight loss and…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
The development of CagriSema represents a significant step towards more effective treatments for Type 2 Diabetes and obesity, conditions that often coexist and exacerbate each other. If the study demonstrates superior…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
This study is crucial as it investigates the effectiveness of low-dose semaglutide in a specific, underrepresented population: obese non-diabetic adults in Pakistan. If successful, the findings could support the broad…
The identification of predictive urinary biomarkers could revolutionize the management of Type 2 Diabetes by enabling truly personalized medicine. This approach could allow clinicians to select the most effective ther…
If successful, this novel approach could offer a significant advancement for patients with Type 2 Diabetes who are dependent on insulin. Reducing or eliminating the need for insulin injections would substantially impr…
Oral semaglutide represents a significant advancement in Type 2 Diabetes management, offering a convenient oral alternative to injectable GLP-1 receptor agonists. Real-world studies like this are vital because they pr…
If successful, this Phase 3 trial could introduce a new, potentially effective treatment option for Type 2 Diabetes patients who require additional glycemic control beyond oral medications. A positive outcome could le…
Obesity-related asthma represents a significant clinical challenge, often resistant to conventional treatments and associated with poorer outcomes. Semaglutide, by targeting obesity and potentially inflammation, offer…
This study is significant as it reinforces the global applicability and consistent safety profile of semaglutide for managing Type 2 Diabetes across diverse ethnic populations. Confirming its tolerability and safety i…
The potential for Semaglutide to cause delayed gastric emptying presents a substantial challenge for surgical planning and patient safety, particularly concerning anesthesia risks. If successful, this study could esta…
The daily burden of carbohydrate counting remains a significant challenge for individuals with Type 1 Diabetes, even with the most advanced closed-loop systems. If weekly Semaglutide proves effective in reducing this …
Understanding the direct haemodynamic mechanisms of semaglutide and tirzepatide is crucial for optimizing their use in patients with cardiovascular diseases. This research could reveal novel pathways through which the…
This real-world SMILE study provides compelling evidence that semaglutide 2.4 mg delivers sustained and clinically meaningful cardiometabolic benefits beyond just weight loss in a diverse patient population. The obser…
This summary from an ICER council is crucial because it provides an independent, evidence-based assessment of the clinical and economic value of two highly effective anti-obesity medications. Such reviews are instrume…
This case report highlights a critical safety concern, suggesting that clinicians should exercise extreme caution when reinitiating GLP-1 receptor agonists like semaglutide after a treatment break. The key implication…
Understanding the specific metabolic shifts induced by Semaglutide and Tirzepatide is crucial for optimizing obesity treatment strategies. If the study reveals significant, sustained improvements in energy expenditure…
This review highlights the significant potential of GLP-1 RAs as a superior therapeutic option for steroid-induced diabetes, moving beyond insulin-centric approaches. Their dual benefits of improving glycemic control …
This study identifies a new genetic cause for FPLD2, specifically the c.604G>C (p.Glu202Gln) variant in the LMNA gene, significantly expanding our understanding of its molecular basis. The discovery of novel pathogeni…
This study provides compelling preclinical evidence that semaglutide, a widely used GLP-1 receptor agonist for type 2 diabetes and obesity, possesses significant neuroprotective properties against chemotherapy-induced…
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
The potential for CagriSema to offer enhanced weight loss beyond current leading therapies like semaglutide represents a significant advancement in treating obesity. If successful, this combination could provide a mor…
Understanding semaglutide's direct neurological effects in healthy individuals is profoundly important for expanding its therapeutic potential. If this study reveals positive acute cognitive or energy-enhancing effect…
This real-world study is crucial for understanding how oral semaglutide performs outside of controlled clinical trials, providing valuable insights into its effectiveness and safety in a diverse patient population und…
While this real-world study involving 388 participants is completed, specific results are pending publication. However, based on extensive prior clinical trials, oral semaglutide is known to significantly improve glyc…
The successful demonstration of feasibility and tolerability could open new avenues for managing obesity in patients with advanced lung disease, potentially improving their quality of life and clinical outcomes. If Se…
Reducing injection site pain is a critical factor for improving patient adherence to long-term therapies like Semaglutide, which is often administered weekly for chronic conditions such as Type 2 Diabetes and Obesity.…
This regulatory post-marketing surveillance study is crucial for gathering real-world evidence on oral semaglutide, complementing data from controlled clinical trials. Such data is vital for understanding how the drug…
This review underscores the critical role of tailored dietary strategies in maximizing the therapeutic benefits of GLP-1 and dual GIP/GLP-1 receptor agonists. It suggests that integrating specific nutritional guidance…
This study provides compelling and definitive evidence that Semaglutide offers direct and substantial cardiovascular benefits in individuals with established cardiovascular disease and overweight or obesity, independe…
This landmark study provides compelling evidence that semaglutide offers significant cardiovascular protection beyond its known weight loss benefits, even in individuals without diabetes. The 20% reduction in major ad…
This study represents a paradigm shift in the management of cardiovascular risk in individuals with obesity. It unequivocally demonstrates that a GLP-1 receptor agonist, semaglutide, can directly reduce major cardiova…
This comprehensive bibliometric analysis provides a crucial roadmap for understanding the evolving landscape of GLP-1 RA adverse effect research. The findings identify key research hotspots and neglected areas, guidin…
This comprehensive meta-analysis solidifies the role of GLP-1 agonists as highly effective treatments for weight loss and improved body composition in adults with overweight or obesity. The significant reduction in fa…
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These …
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…